Welcome to the Ojima Research Group Website
Synthetic Organic and Medicinal Chemistry at the Biomedical Interface
Discovery and development of new and potent anticancer agents, antibacterial agents, anti-inflammatory agents, and various enzyme inhibitors are the major research interests in Professor Ojima's laboratory. Integration of all relevant chemistry and biological tools, including computational biology (docking, in silico screening, molecular dynamics), chemical biology (protein expression, enzyme assays, fluorescence labeling), cell biology (cell culture, cytotoxicity assay, fluorescent confocal microscopy, flow cytometry, transmission and scanning electron microscopy), has successfully been realized in this program. Naturally, this research program is promoted in close collaboration with cell biologists, oncologists, microbiologist, pharmacologists, hematologists, toxicologists, etc., as well as the Division of Laboratory Animals Resources for in vivo efficacy evaluations. The Ojima Laboratory has also been exploring and developing new synthetic methodologies, especially based on catalytic organic transformations, including enantioselective processes, cyclohydrocarbonylations and higher order cycloadditions and carbocyclizations, which provide the basis for the efficient syntheses of biologically active substances of medicinal interest, such as those anticancer and antibacterial agents mentioned above.
Ojima Research Group 2024
News
Congratulation to Dr. Ashna Garg for successfully defending her thesis!
Katie Shou and Prof. Ojima were featured in the Stony Brook Magazine
Congratulations to Simon's Summer Research students Katie Shou, Allyson Wong and Elizabeth Xiu for finishing the program!
Congratulations to Dr. Kalani Jayanetti for successfully defending her thesis!
Congratulations to our graduates Ashna Garg, Kalani Jayanetti, Jacob Acosta, Binna Chen, Saba Gulzar and Yuxuan Zhang!
The Ojima Distinguished Lectureship Award was presented to Prof. Hikoaki Suga
More News
Research
Next-Generation Pain Control with Novel Stony Brook Fatty Acid Binding Protein (FABP) Inhibitors (SB-FIs)
FABP Inhibitors (SB-FIs) as New-Generation Anticancer Agents
Novel Antifungal Acylhydrazones
Sterylglucosidase Inhihibitors as Novel Antifungal Agents
Next-Generation Taxoids as Potent and Efficacious Anticancer Agents
Tumor-Targeted Delivery of Highly Potent Taxoid Anticancer Agents
Prof. Iwao Ojima
Congratulations to Prof. Ojima for being elected as a Fellow to the European Academy of Sciences!